Chronic Pain Isn’t “In Your Head”—It’s an Energy Crisis: The Mitochondria–Inflammation Loop (and Where Red Light Fits)
The Energy Code
Outro
Mike closes the episode, invites sharing, ratings, and points listeners to biolite.shop and his social channels.
This episode builds a real framework for chronic pain by connecting two worlds that rarely get stitched together: (1) a mechanistic review arguing that mitochondrial dysfunction drives pain chronification, and (2) a systematic review of randomized clinical trials on photobiomodulation (PBM) — red/near-infrared light therapy — for chronic pain. Dr. Mike Belkowski explains why chronic pain is a bioenergetic + redox + immune signaling loop (ATP instability, mitochondrial ROS, calcium overload, neuroinflammation, and quality-control failure), then maps where PBM appears to help most in humans (especially fibromyalgia and peripheral neuropathies) while being honest about the biggest limitation: protocol variability. The punchline is practical and responsible: PBM isn’t a stand-alone magic fix — it’s best viewed as a mitochondria-targeted module inside a larger systems strategy.
(Educational content only, not medical advice.)
-
Articles Discussed in Episode:
Mitochondrial Dysfunction as a Driver of Chronic Pain: New Insights and Therapeutic Prospects
Photobiomodulation in chronic pain: a systematic review of randomized clinical trials
-
Key Quotes From Dr. Mike:
“Chronic pain is a bioenergetic problem…”
“What makes chronic pain chronic is that the pain system changes.”
“Pain transmission is expensive. Every action potential costs energy.”
“PBM… may be one of the cleanest real-world tests of a mitochondria-first pain model.”
“PBM should be seen as a module inside a larger system strategy, not a magic stand-alone fix.”
-
Key Points
-
Chronic pain persists because the pain system changes: sensitization + amplification (“gain knob” turned up).
-
Pain transmission is energy expensive; mitochondrial strain makes neurons hyperexcitable.
-
The chronification loop: ATP instability → ROS amplification → calcium dysregulation/MPTP risk → mtDAMPs → NLRP3 + cytokines → glial amplification → more excitability → more mitochondrial damage.
-
Mitochondrial quality control fails in chronic pain: mitophagy ↓, biogenesis ↓ (PGC-1α/NRF1/TFAM), dynamics skew (DRP1), transport disrupted.
-
PBM is a strong real-world test because it’s fundamentally a mitochondria-influencing signal.
-
RCT review (2015–2025) finds PBM often reduces pain, most consistently in fibromyalgia and peripheral neuropathies, with low adverse events.
-
The limiting factor is heterogeneity: wavelengths, dose, frequency, devices, outcome measures, and follow-up windows vary widely.
-
Responsible take: PBM is best viewed as a module inside a larger system strategy, not a stand-alone fix.
-
Timing matters: pain chronification is a trajectory; earlier intervention may prevent “lock-in,” later intervention typically requires stacked strategies.
-
Episode timeline
-
0:41–1:33 — Mission: connect mechanistic model to RCT evidence; what each source is
-
1:48–2:56 — Unified pain-energy model + disclaimer
-
2:56–3:40 — Definition: pain persists because the system changes; “gain knob” up
-
3:45–6:07 — Mechanistic engine: energy crisis → ROS → calcium/MPTP → mtDAMPs/NLRP3 → QC failure → lock-in
-
6:14–6:54 — Clinical trials review summary: PBM often helps (fibromyalgia/neuropathy), but variability limits standardization
-
7:11–8:53 — Step 1: energy failure; “unstable bioenergetics”
-
8:53–10:18 — Step 2: mitochondrial ROS as a signaling amplifier
-
10:18–12:12 — Step 3: calcium overload + permeability transition
-
12:12–14:07 — Step 4: mtDAMPs → neuroinflammation → central sensitization loop
-
14:11–16:36 — Step 5: quality control failure + cell-type specificity (neurons, glia, Schwann cells)
-
16:36–19:06 — Pain types where mitochondrial signatures show up; therapy implications (mitoQ/mitoTEMPO, melatonin, NAD+ precursors, SS-31, etc.)
-
19:12–21:54 — PBM mechanisms + what RCTs found + heterogeneity
-
21:54–26:15 — Compare/contrast: where sources agree, where they differ, why they complement
-
26:22–27:18 — Integrated conclusion: mito-first model predicts PBM works best in sensitization/metabolic stress phenotypes
-
27:31–30:40 — Practice implications in layers (remove stressors → restore QC → PBM module → precision targeting)
-
30:40–31:08 — “Not in your head” clarification: it’s physiology
-
31:16–33:42 — Responsible PBM conclusion: promising, safe profile, needs standardization/long follow-up
-
34:16–34:57 — Time matters: acute → chronic trajectory
-
34:59–37:38 — BioLight framing + 3 conclusions (engine > symptom suppression; PBM isn’t woo; future = precision)
-
Dr. Mike's #1 recommendations:
Deuterium depleted water: Litewater (code: DRMIKE)
EMF-mitigating products: Somavedic (code: BIOLIGHT)
Blue light blocking glasses: Ra Optics (code: BIOLIGHT)
Grounding products: Earthing.com
-
Stay up-to-date on social media:
Dr. Mike Belkowski:
BioLight:
The AI-powered Podcast Player
